| Literature DB >> 33807486 |
Ivana Mareković1, Sanja Pleško1, Violeta Rezo Vranješ1, Zoran Herljević1, Tomislav Kuliš2, Marija Jandrlić1.
Abstract
Invasive candidosis is the most common invasive fungal infection in hospitalized patients and is associated with a high mortality rate. This is the first study from a Croatian tertiary care hospital describing epidemiology, risk factors and species distribution in patients with candidemia. A three-year retrospective observational study, from 2018 to 2020, was performed at the University Hospital Centre Zagreb, Zagreb, Croatia. A total of 160 patients with candidemia (n = 170 isolates) were enrolled. Candidemia incidence increased from 0.47 to 0.69 per 1000 admissions in 2018 and 2020, respectively. Ninety-five patients (58.38%) were in the intensive care unit. The main risk factors for candidemia were central venous catheter (CVC) (84.38%), previous surgical procedure (56.88%) and invasive mechanical ventilation (42.50%). Candida albicans was identified in 43.53% of isolates, followed by C. parapsilosis (31.76%) and C. glabrata (12.36%), C. krusei (5.29%), C. tropicalis (2.35%) and C. lusitaniae (2.35%). The study discovered a shift to non-albicansCandida species, particularly C. parapsilosis, and made it possible to determine the main tasks we should focus on to prevent candidemia in the hospital, these being mainly infection control measures directed towards prevention of catheter-related bloodstream infections, specifically comprising hand hygiene and CVC bundles of care. The potential benefit of fluconazole prophylaxis in certain populations of surgical patients could also be considered.Entities:
Keywords: blood culture; candidemia; central venous catheter; epidemiology; risk factors
Year: 2021 PMID: 33807486 PMCID: PMC8065499 DOI: 10.3390/jof7040267
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
Number of patients with candidemia, Candida spp. isolates, hospital admissions and incidence rates in three-year study period (2018–2020).
| 2018 | 2019 | 2020 | |
|---|---|---|---|
| Number of patients with candidemia | 50 | 58 | 52 |
| Number of | 54 | 58 | 58 |
| Hospital admissions | 106,186 | 88,003 | 75,023 |
| Incidence per 1000 admissions | 0.47 | 0.66 | 0.69 |
Demographic data and clinical characteristics of 160 patients with candidemia.
| Median:Mean (Range) or n (%) | |
|---|---|
| Age (years) | 62:51.65 (0–86) |
| Gender (male) | 87 (54.38) |
| Clinical characteristic a | |
| Central venous catheter | 135 (84.38) |
| Intensive care unit | 95 (59.38) |
| Previous surgical procedure | 91 (56.88) |
| Type of surgical procedure | |
| Abdominal | 39 (24.38) |
| Cardiac | 13 (8.13) |
| Thoracic | 14 (8.75) |
| Vascular | 11 (6.88) |
| Neurosurgery | 7 (4.38 |
| Orthopedic | 2 (1.25) |
| Multiple trauma | 0 |
| Solid organ transplant | 1 (0.63) |
| Other | 6 (3.75) |
| Repeated surgery | 54 (33.75) |
| Invasive mechanical ventilation | 68 (42.50) |
| Total parenteral nutrition | 56 (35.00) |
| Solid tumor | 40 (25.00) |
| Hematological malignancy | 23 (14.38) |
| Dialysis at presentation | 23 (14.38) |
| Diabetes mellitus | 22 (13.75) |
| Pancreatitis | 4 (2.50) |
| Burns | 0 |
| Human immunodeficiency virus | 0 |
a some patients had more than one clinical characteristic.
Species distribution of Candida isolates in the three-year study period (2018–2020).
| 2018 | 2019 | 2020 | Total | |
|---|---|---|---|---|
|
| 24 (44.45%) | 24 (41.38%) | 26 (44.83%) | 74 (43.53%) |
|
| 19 (35.19%) | 21 (36.20%) | 14 (24.15%) | 54 (31.76%) |
|
| 7 (12.96%) | 7 (12.07%) | 7 (12.07%) | 21 (12.36%) |
|
| 1 (1.85%) | 4 (6.90%) | 4 (6.90%) | 9 (5.29%) |
|
| 1 (1.85%) | 0 | 3 (5.17%) | 4 (2.35%) |
|
| 2 (3.70%) | 2 (3.45%) | 0 | 4 (2.35%) |
|
| 0 | 0 | 1 (1.72%) | 1 (0.59%) |
|
| 0 | 0 | 1 (1.72%) | 1 (0.59%) |
|
| 0 | 0 | 1 (1.72%) | 1 (0.59%) |
|
| 0 | 0 | 1 (1.72%) | 1 (0.59%) |
| Total | 54 | 58 | 58 | 170 |
Independent risk factors associated with the three most frequently isolated Candida spp. (n = 151).
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| |
|---|---|---|---|---|---|---|---|---|---|
| Age | 0.98 | 0.97–1.0 | 0.011 | 1.05 | 1.01–1.08 | 0.011 | |||
| Diabetes mellitus (21) | 4.21 | 1.48–12.3 | 0.007 | ||||||
| Total parenteral nutrition (53) | 0.38 | 0.15–0.97 | 0.042 | 5.09 | 1.24–20.84 | 0.024 | |||
| Invasive mechanical ventilation (64) | 2.17 | 0.88–5.40 | 0.094 | 0.20 | 0.05–0.86 | 0.030 | |||
| Central venous catheter (126) | 0.40 | 0.16–1.05 | 0.063 | 6.07 | 1.60–23.01 | 0.008 | |||
OR: odds ratio, CI: confidence interval; the cut-off p value for variables selected in the backward stepwise logistic regression was 0.10.; patients with mixed infections were not included in the analysis.
Figure 1Proportion rate of C. albicans and non-albicans Candida species during the three-year study period.
Susceptibility to antifungal agents of the three most frequently isolated Candida spp. in the period 2019–2020.
| Number (%) of Isolates | ||||
|---|---|---|---|---|
| Species | Antifungal Agent | Susceptible | Susceptible Dose-Dependent | Resistant |
| Fluconazole | 49 (96.08) | 0 | 2 (3.92) | |
| Anidulafungin | 49 (96.08) | 1 (1.96) | 1 (1.96) | |
| Caspofungin | 48 (94.12) | 0 | 3 (5.88) | |
| Micafungin | 49 (96.08) | 0 | 2 (3.92) | |
| Amphotericin B | 51 (100.0) | 0 | 0 | |
| Fluconazole | 6 (16.67) | 6 (16.67) | 30 (83.33) | |
| Anidulafungin | 30 (83.33) | 5 (13.89) | 1 (2.78) | |
| Caspofungin | 36 (100.0) | 0 | 0 | |
| Micafungin | 34 (94.4) | 2 (5.56) | 0 | |
| Amphotericin B | 36 (100.0) | 0 | 0 | |
| Fluconazole | 0 | 10 (71.43) | 4 (28.57) | |
| Anidulafungin | 14 (100.0) | 0 | 0 | |
| Caspofungin | 13 (92.86) | 1 (7.14) | 0 | |
| Micafungin | 14 (100.0) | 0 | 0 | |
| Amphotericin B | 14 (100.0) | 0 | 0 | |